Hogan Lovells Cadwalader advises Organigram on CAD561 million acquisition of Aurora Cannabis
Organigram to acquire Aurora Cannabis in a CAD561M deal, pending approvals. The combined entity will operate five EU-GMP-certified facilities. Completion is expected in January 2027. Hogan Lovells Cadwalader and Goodmans LLP advised on the transaction.
How this was made
The 30-second read
Why it matters
The merger creates a vertically integrated cannabis company with expanded geographic reach, potentially improving margins.
Market read
First‑report M&A news with a $400 M‑plus valuation, likely to move both stocks and influence the broader cannabis sector.
What to watch
Regulatory approvals in Europe and the U.S. could delay or derail the transaction, adding execution risk.
Background
The deal combines Organigram's Canadian recreational market leadership with Aurora's medical platform and European facilities.
Ticker impact
Organigram announced a CAD 561 million acquisition of Aurora Cannabis, subject to approvals and expected to close Jan 2027.
likely downside for OGI as the acquirer, likely upside for ACB as the target
Acquisition announcements typically lift the target stock and weigh on the buyer due to financing and integration risk.
Aurora Cannabis is being acquired by Organigram for CAD 561 million, pending shareholder and regulatory approvals.
upward pressure as the target in a cash‑plus‑stock deal
Deal terms imply a premium to Aurora's current market price, driving short‑term upside.
Market effects
Consolidation in the Canadian cannabis sector may spur further M&A activity.
Potential uplift for Canadian cannabis stocks as the deal signals industry maturation.
Limited global impact, but may affect investors with exposure to cannabis ETFs.
Counterpoint
If financing costs rise, the acquisition could strain Organigram's balance sheet, leading to a sharper sell‑off.
Key entities
- CompanyOrganigram Inc.
Canadian recreational cannabis producer and acquirer.
- CompanyAurora Cannabis Inc.
Global medical cannabis operator and acquisition target.
